Jubilant Life Sciences' (JUBL) Q4FY19 revenue grew marginally by 6% YoY as the growth in the pharma (59% of Q4FY19 revenue) and DDS (3%) segments was muted by a decline in the LSI (38%) segment. RubyFill continues to gain market share, but the company is currently incurring costs to develop the market for future revenue and higher margins. Triad to breakeven in FY21. LSI was impacted by a sharp drop in acetic acid prices (from USD 600 during 9MFY19 to USD 450 in Q4FY19), high inventory cost, and pricing pressure for molasses. JUBL guided that there will be product launches and capacity...